This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Sep 27;8(11):610.

doi: 10.1038/nrcardio.2011.150.

Coronary artery disease: Dalcetrapib safely raises HDL-cholesterol level in the phase IIb dal-PLAQUE trial

PMID: 21946777
DOI: 10.1038/nrcardio.2011.150

Comment

Coronary artery disease: Dalcetrapib safely raises HDL-cholesterol level in the phase IIb dal-PLAQUE trial

Gregory B Lim. Nat Rev Cardiol. 2011.

. 2011 Sep 27;8(11):610.

doi: 10.1038/nrcardio.2011.150.

Author

PMID: 21946777
DOI: 10.1038/nrcardio.2011.150

No abstract available

PubMed Disclaimer

Comment on

Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial.
Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, Fuster V, Ballantyne CM, Stein EA, Tardif JC, Rudd JH, Farkouh ME, Tawakol A; dal-PLAQUE Investigators. Fayad ZA, et al. Lancet. 2011 Oct 29;378(9802):1547-59. doi: 10.1016/S0140-6736(11)61383-4. Epub 2011 Sep 9. Lancet. 2011. PMID: 21908036 Free PMC article. Clinical Trial.

References

1. Lancet. 2011 Oct 29;378(9802):1547-59 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.